NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

WithdrawnPhase 2

Sponsor: University of Minnesota

Conditions: Fabry Disease, Neuropathic Pain

Interventions: Gabapentin, placebo

Countries: United States

The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain in patients with Fabry disease, and reducing their use of opioid analgesics. The investigators are conducting a randomized, double-blind, placebo controlled, single center, cross-over study. The primary endpoint is percent reduction in patients' use of hydrocodone-acetaminophen.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* diagnosis of Fabry Disease
* age ≥ 18 years of age at study enrollment
* current neuropathic pain at any severity level

Exclusion Criteria:

* known sensitivity or allergy to study drug
* history of illicit drug use
* pregnancy
* suicidal thoughts at study enrollment as assess by the C-SSRS

Locations (1)

Minneapolis, Minnesota, United States